The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Novartis; Pierre Fabre; Roche; Sanofi
 
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
 
Helen Gogas
Honoraria - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb; MSD Oncology; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Roche
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; Italfarmaco; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Keith Flaherty
Stock and Other Ownership Interests - Apricity Health; Checkmate Pharmaceuticals; Clovis Oncology; FOGPharma; Fount Therapeutics; Kinnate Biopharma; Loxo; Oncoceutics; PIC Therapeutics; Shattuck Labs; Strata Oncology; Tvardi Therapeutics; X4 Pharma
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Array BioPharma; Asana Biosciences; Boston Biomedical; Bristol-Myers Squibb; Cell Medica; Debiopharm Group; FOGPharma; Genentech; Incyte; Lilly; Loxo; Merck; Neon Therapeutics; Novartis; Oncoceutics; Pierre Fabre; Roche; Sanofi; Shattuck Labs; Takeda; Tolero Pharmaceuticals; Tvardi Therapeutics; Verastem
Research Funding - Novartis; Sanofi
Travel, Accommodations, Expenses - Debiopharm Group; Pierre Fabre
 
Ana Arance
No Relationships to Disclose
 
Mario Mandalà
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
 
Gabriella Liszkay
Consulting or Advisory Role - Amicus Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
 
Claus Garbe
Honoraria - Amgen; Bristol-Myers Squibb; MSD Oncology; NeraCare GmbH; Novartis; Philogen; Roche/Genentech; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; NeraCare GmbH; Novartis; Philogen; Roche/Genentech; Sanofi
Research Funding - Bristol-Myers Squibb; NeraCare GmbH; Novartis; Roche/Genentech
 
Dirk Schadendorf
Honoraria - 4SC; Array BioPharma; Bristol-Myers Squibb; Immunocore; Incyte; InflarxGmbH; Merck Serono; Merck Sharp & Dohme; Mologen; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Incyte; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Incyte; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Ivana Krajsova
No Relationships to Disclose
 
Ralf Gutzmer
Honoraria - Almirall Hermal GmbH; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - 4SC; Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Incyte; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Pierre Fabre; Roche; Sun Pharma
 
Jan Willem de Groot
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER
 
Caroline Dutriaux
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Carmen Loquai
Honoraria - Amgen; BioNTech; Bristol-Myers Squibb; LEO Pharma; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sun Pharma
 
Ashwin Gollerkeri
Employment - Alnylam (I); Array BioPharma; Bluebird Bio (I); Pfizer
Stock and Other Ownership Interests - Alnylam (I); Array BioPharma; Bluebird Bio (I); Pfizer
Patents, Royalties, Other Intellectual Property - Receives royalties from Yale University on an antibody used in nephrology basic research. (I)
 
Michael D Pickard
Employment - Pfizer
 
Caroline Robert
Consulting or Advisory Role - Amgen; Biothera; Bristol-Myers Squibb; CureVac; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)